Tag: nasdaq:prqr

October 10, 2019

ProQR Announces Positive Phase 1/2 Study of Sepofarsen

The company announced topline results for its PQ-110-001 study in patients with Leber's congenital amaurosis 10 (LCA10).
August 12, 2019

ProQR Receives IND Clearance to Start Clinical Trial of QR-1123

ProQR Therapeutics (NASDAQ:PRQR) has announced that the US Food and Drug Administration (FDA) has cleared the company’s investigational new drug...
December 24, 2018

ProQR Therapeutics Added to NASDAQ Biotechnology Index

ProQR Therapeutics (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of...
October 29, 2018

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

ProQR Therapeutics (Nasdaq:PRQR) a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of...
October 3, 2018

VIDEO — Life Science Update September 2018

With September officially behind us, the Investing News Network is taking a look back at some of the biggest news...
September 5, 2018

ProQR’s Share Price Soars with Positive Interim Results

Shares of the company spiked 120.75 percent on Wednesday on the back of a Phase 1/2 clinical trial of QR-110...
September 5, 2018

ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

ProQR Therapeutics (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of...